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Editorial
Raising a glass to  
personalized medicine
It’s a little late to wish you a Happy New 
Year but as this is the first issue of 2016, it seems 
appropriate to reflect on the making and breaking 
of New Year’s resolutions. As I write, the UK is 
coming to the end of “Dry January”- a seasonal 
antidote to festive drinking excesses, encouraged 
no doubt by various scaremongering articles in 
the national press. I tend not to believe much that 
I read in the tabloids and confess that my January was not as dry as it might 
have been (unless the enjoyment of an astringent Bourgogne Aligoté counts 
on the “dry” front). However, when Nature editorials discuss reducing 
alcohol consumption in the context of evidence-based policy1 then it’s 
time to take note. The UK Chief Medical Officers recently issued a new 
set of guidelines for safe alcohol consumption2. Perhaps the most striking 
recommendation is that men should not be drinking more than women 
(the recommended weekly limit is 14 units for both sexes), challenging the 
tacit assumption that men, with their larger livers, can tolerate more booze. 
Whilst these blanket recommendations have in some quarters been 
celebrated as a triumph for evidence-based policymaking, it did occur to me 
that they appear to neglect an important consideration: individual variation. 
I have an acquaintance who is rendered almost insensible by a small glass of 
wine and yet others who appear to be able to consume industrial quantities 
of beer without apparent loss of social function. A plethora of biochemical, 
physiological and behavioural differences underpin these extreme levels 
of tolerance. This fact is not ignored in the Chief Medical Officers’ longer 
report, which remarks, somewhat soberly: “People vary in how they 
metabolize or react to alcohol, so people can be affected differently by 
drinking similar amounts.” However, there is little room for nuance when 
issuing a clear set of health guidelines and an unequivocal message needs 
to be communicated.
Personalized medicine offers an almost infinite potential for nuance 
in diagnosis and treatment. Although not a new idea (Hippocrates, it 
seems was first on record to advocate the benefits of tailoring therapy to 
the individual), advances in all types of ‘omics and importantly, dramatic 
reduction in the cost of DNA sequencing now offer unparalleled 
opportunities to understand the causes of disease and customise 
interventions for different patients. As the articles in this issue attest, several 
conditions already benefit from targeted therapies, but much more is in the 
pipeline as increasing numbers of genomes are scrutinised.  Announcing 
its first diagnoses of rare diseases in children at the start of 2016, the 
100,000 Genomes Project also targets cancer and has been hailed as the 
“beginning of the end of chemotherapy”. Personalized medicine is not 
without its challenges: ethical, social, economic, as well as intellectual, but it 
offers superb promise in transforming healthcare. I’ll raise a glass to that ■ 
1. Solving the drink problem. Nature Jan 13, p27
2. http://www.cpwy.org/doc/1128.pdf
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